Tamaki H, Amino N, Kimura M, Hidaka Y, Takeoka K, Miyai K
Department of Laboratory Medicine, Osaka University Medical School, Japan.
J Clin Endocrinol Metab. 1990 Nov;71(5):1382-6. doi: 10.1210/jcem-71-5-1382.
The prevalence of TSH receptor antibody (TRAb), measured by RRA assay (TSH-binding inhibitor immunoglobulin, TBII) and biological stimulation-blocking assay (thyroid-stimulation blocking antibody, TSBAb), was examined in 134 consecutive patients with primary hypothyroidism due to autoimmune thyroiditis [83 patients with goitrous Hashimoto's disease (group A) and 51 with primary atrophic hypothyroidism (group B)]. In group A, TBII was detected in 6 patients (7%), TSBAb in 7 (8%), and both in 4 (5%). Similarly, in group B, TBII was detected in 7 patients (14%), TSBAb in 7 (14%), and both in 5 (10%). TBII with TSBAb activity was low or moderate in group A, but strongly positive in group B. No relationship was apparent in either group between TBII or TSBAb activity and any clinical or laboratory parameter examined. Moreover, no clinical or laboratory findings distinguished patients with TRAb from those without. The low prevalence of TRAb in primary hypothyroidism suggests that intrathyroidal cell-mediated destructive mechanisms may be more important in the pathogenesis of hypothyroidism in autoimmune thyroiditis.
采用放射受体分析法(促甲状腺激素结合抑制免疫球蛋白,TBII)和生物刺激阻断分析法(甲状腺刺激阻断抗体,TSBAb)检测了134例因自身免疫性甲状腺炎导致的原发性甲状腺功能减退症患者的促甲状腺激素受体抗体(TRAb)患病率[83例患有甲状腺肿性桥本氏病的患者(A组)和51例原发性萎缩性甲状腺功能减退症患者(B组)]。在A组中,6例患者(7%)检测到TBII,7例(8%)检测到TSBAb,4例(5%)两者均检测到。同样,在B组中,7例患者(14%)检测到TBII,7例(14%)检测到TSBAb,5例(10%)两者均检测到。A组中具有TSBAb活性的TBII为低或中度阳性,但在B组中为强阳性。在两组中,TBII或TSBAb活性与所检查的任何临床或实验室参数之间均无明显关系。此外,没有临床或实验室检查结果能够区分有TRAb的患者和没有TRAb的患者。原发性甲状腺功能减退症患者中TRAb的患病率较低,这表明甲状腺内细胞介导的破坏机制在自身免疫性甲状腺炎所致甲状腺功能减退症的发病机制中可能更为重要。